Research Analysts’ Weekly Ratings Changes for Ralliant (RAL)

Ralliant (NYSE: RAL) recently received a number of ratings updates from brokerages and research firms:

• 7/20/2026 – Ralliant is now covered by BMO Capital Markets. They set a “market perform” rating and a $78.00 price target on the stock.
• 7/20/2026 – Ralliant is now covered by BMO Capital Markets. They set a “hold” rating and a $78.00 price target on the stock.
• 7/18/2026 – Ralliant was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/16/2026 – Ralliant had its price target raised by Royal Bank Of Canada from $64.00 to $71.00. They now have a “sector perform” rating on the stock.
• 7/13/2026 – Ralliant had its price target raised by Citigroup Inc. from $70.00 to $81.00. They now have a “buy” rating on the stock.
• 6/30/2026 – Ralliant was upgraded by Zacks Research from “hold” to “strong-buy”.
• 6/28/2026 – Ralliant was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/23/2026 – Ralliant had its price target raised by Morgan Stanley from $68.00 to $85.00. They now have an “overweight” rating on the stock.
• 6/20/2026 – Ralliant was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/9/2026 – Ralliant is now covered by Evercore Inc. They set an “outperform” rating and a $80.00 price target on the stock.
• 5/31/2026 – Ralliant was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/27/2026 – Ralliant was downgraded by Vertical Research from “buy” to “hold”. They now have a $65.00 price target on the stock.
• 5/23/2026 – Ralliant was upgraded by Wall Street Zen from “hold” to “buy”.

Ralliant Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is -1.83%.

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.